logo.gif
BGHL (GBP): NAV(s)
December 04, 2019 01:30 ET | BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)
                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
logo.gif
BGHL (EUR): NAV(s)
December 04, 2019 01:30 ET | BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
Regarding the working group, initiated by the Ministry of Finance of the Republic of Lithuania, the authority implementing the rights of the sole shareholder of UAB Ignitis grupė
December 04, 2019 01:00 ET | Lietuvos Energija
UAB Ignitis grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000...
Novadip logo.png
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science
December 04, 2019 01:00 ET | Novadip Biosciences
Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences...
INNATEvertnoir.png
INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020
December 04, 2019 01:00 ET | INNATE PHARMA
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar: March 10, 2020:         Publication of 2019 financial statements, with...
logo.png
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
December 04, 2019 01:00 ET | F. Hoffmann-La Roche Ltd
      ·Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Basel, 4...
Start of Day Message
December 04, 2019 01:00 ET | GlobeNewswire, Inc.
LONDON, 04 Dec. 2019 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by West Corporation and is designated by the FCA as an approved primary...
Schibsted_Logotype_L1_Dust-black_RGB-300x54.png
Schibsted ASA (SCHA/SCHB) – Share buyback
December 04, 2019 01:00 ET | Schibsted
Schibsted has on 03 December 2019 purchased 42,000 own A-shares at an average price of NOK 251.5029 per share and 19,000 own B-shares at an average price of NOK 236.3942 on the Oslo Stock Exchange....
MAUI LAND & PINEAPPLE ANNOUNCES REPAIR TO THE WEST MAUI DITCH
December 04, 2019 00:57 ET | Maui Land & Pineapple Company, Inc.
KAPALUA RESORT, Hawaii, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Maui Land & Pineapple Company, Inc. (“MLP”) (NYSE: MLP) today announced that major repairs of the West Maui ditch system are underway to...
logo.jpg
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
December 04, 2019 00:45 ET | ImCheck Therapeutics SAS
-- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class...